全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
华西医学  2012 

噻托溴铵在慢性阻塞性肺疾病急性加重期治疗的临床观察

, PP. 1859-1861

Keywords: 噻托溴铵,慢性阻塞性肺疾病急性加重期,肺功能,呼吸困难评分,血气分析

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的 观察噻托溴铵治疗慢性阻塞性肺疾病急性加重期(AECOPD)的疗效。方法 将2010年5月-2012年4月住院的100例年龄50~80岁的中重度AECOPD患者随机分为治疗组(50例)和对照组(50例)。对照组给予吸氧、止咳、祛痰、雾化吸入布地奈德4mL+硫酸特布他林4mL(2次/d)抗炎,氨茶碱扩张气道,以及静脉使用抗生素抗感染、支持等常规治疗,治疗组在常规治疗基础上给予噻托溴铵干粉剂(18μg,1次/d)吸入,疗程14d。观察两组用药前后肺功能指标,呼吸困难评分以及血气分析指标的变化。结果 两组患者用药后肺功能、呼吸困难评分及血气分析均较治疗前有明显改善,用药后与用药前比较差异有统计学意义(P<0.05);治疗组改善更明显,与对照组比较差异有统计学意义(P<0.05)。结论 噻托溴铵能明显改善中重度AECOPD患者的呼吸困难,肺功能及血气分析指标。

References

[1]  [ 1 ] 中华医学会呼吸病学分会慢性阻塞性肺疾病. 慢性阻塞性肺疾病诊疗指南(2007年修订版)[J]. 中华结核和呼吸杂志, 2007, 30(1): 8-17.
[2]  [ 2 ] Rabe KF, Hurd S, An zueto A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary[J]. Am J Respir Crit Care Med, 2007, 9(6): 532-555.
[3]  [ 3 ] Anzueto AR. Answers to 5 common questions about acute exacerbations of COPD[J]. Postgrad Med, 2009, 121(5): 159-165.
[4]  [ 4 ] Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once -daily inhaled tiotropium in chronic obstructive pulmonary disease[J] . Eur Respir J, 2002, 19(2): 217-224.
[5]  [ 5 ] Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium[J] . Eur Respir J, 2002, 19(2): 209-216.
[6]  [ 6 ] Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary[J]. Am J Respir Crit Care Med, 2001, 163(5): 1256?1276.
[7]  [ 7 ] Kirkpatrick CJ, Bittinger F, Nozadze K, et al. Expression and function of the non-neuronal cholinergic system in endothelial cells [J]. Life Sci, 2003, 72(18/19): 2111-2116.
[8]  [ 8 ] Barnes PJ. Distribution of receptor targets in the lung[J]. Proceed Am Thorac Soc, 2004, 1(4): 345-351.
[9]  [ 9 ] Barnes PJ. Mechanisms in COPD: differences from asthma[J]. Chest, 2000, 117(Suppl 2):10-14.
[10]   Barnes PJ. Tiotropium bromide[J]. Expert Opin Investig Drugs, 2001, 10(4): 733-740.
[11]   Calverly PMA, Towse LJ, Lee A. The timing of dose and pattern of bronchodilation of tiotropium (TIO) in stable COPD[J]. Eur Respir J, 2000, 16(31) : 56.
[12]   Disse B, Speck G A, Rominger K L, et al. Tiotropium (spiriva) : mechanical considerations and clinical profile in obstructive lung disease[J]. Life Sci, 1999, 64(6/7): 457-464.
[13]   Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases[J]. Pharmacol Ther, 2003, 98(1): 59-69.
[14]   Vacca G, Randerath WJ, Gillissen A. Inhibition of granulocyte migration by tiotropium bromide[J]. Respir Res, 2011, 12(1): 24.
[15]   Koarai A, Traves SL, Fenwick PS, et al. Expression of muscarinic receptors by human macrophages[J]. Eur Respir J, 2012, 39(3): 698-704.
[16]   Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide[J]. Life Sci, 2007, 80(24-25): 2270-2273.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133